Related Experiment Video

Updated: May 24, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Cardiotrophin-1 in hypertensive heart disease

Arantxa González1, Begoña López, Susana Ravassa

  • 1Área de Ciencias Cardiovasculares, Centro de Investigación Médica Aplicada, Universidad de Navarra, Av. Pío XII 55, 31008, Pamplona, Spain.

Endocrine
|March 16, 2012
PubMed

Insights

Cardiotrophin-1, a cytokine involved in myocardial remodeling, may be a key factor in hypertensive heart disease. It shows promise as a biomarker and therapeutic target for left ventricular hypertrophy and heart failure.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Hypertension Research

Background:

  • Hypertensive heart disease involves complex myocardial structural changes leading to left ventricular dysfunction and heart failure.
  • Mechanical, neurohormonal, and cytokine pathways contribute to myocardial remodeling in hypertension.
  • Cardiotrophin-1 (CT-1), a cytokine, is implicated in cardiomyocyte hypertrophy and myocardial fibrosis.

Purpose of the Study:

  • To explore the role of cardiotrophin-1 in the pathogenesis of hypertensive heart disease.
  • To investigate cardiotrophin-1 as a potential biomarker for left ventricular hypertrophy and dysfunction.
  • To assess cardiotrophin-1 as a therapeutic target for hypertensive heart disease.

Main Methods:

  • Review of existing literature on cardiotrophin-1 and hypertensive heart disease.
  • Analysis of signaling pathways involving cardiotrophin-1, gp130, and gp90.
  • Evaluation of cardiotrophin-1's potential as a biomarker and therapeutic target.

Main Results:

  • Cardiotrophin-1 is produced by cardiomyocytes and non-cardiomyocytes under biomechanical stress.
  • CT-1 signaling activates pathways leading to cardiomyocyte hypertrophy and myocardial fibrosis.
  • Evidence suggests CT-1 may serve as a biomarker for left ventricular hypertrophy and dysfunction.

Conclusions:

  • Cardiotrophin-1 plays a significant role in the structural and functional changes of hypertensive heart disease.
  • CT-1 represents a promising biomarker for identifying patients at risk of left ventricular hypertrophy and dysfunction.
  • Targeting cardiotrophin-1 may offer a novel therapeutic strategy for hypertensive heart disease, complementing blood pressure control.

More Related Videos

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model10:18

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model

Published on: June 29, 2014

Transverse Aortic Constriction in Mice08:25

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy: physiological...